Direct oral anticoagulants were associated with lower risks of ischemic stroke or systemic embolism and bleeding compared with warfarin. The study included patients with atrial fibrillation (AF) and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window It was safe to ...

(WASHINGTON, June 6, 2024) – Patients with atrial fibrillation (Afib) who took low doses of blood-thinning medications known as direct oral anticoagulants (DOACs) experienced more bleeding episodes ...

Apixaban or rivaroxaban may be no safer than warfarin with respect to fracture risk in patients with CKD and atrial fibrillation. Despite earlier favorable reports, fracture risk is comparable between ...

Patients with atrial fibrillation (Afib) who took low doses of blood-thinning medications known as direct oral anticoagulants (DOACs) experienced more bleeding episodes during the first three months ...

Using direct oral anticoagulants as a case study, the authors examined how delayed adoption of novel treatments could impact patient health outcomes and cost. Objective: To examine the relationship ...

Please provide your email address to receive an email when new articles are posted on . Abridged dual therapy followed by direct oral anticoagulant monotherapy after PCI may be safe vs. 1 year of dual ...

Left atrial appendage closure was associated with about half as many disabling or fatal strokes and lower mortality after a stroke compared with dual oral anticoagulant therapy in patients with atrial ...

SAN FRANCISCO, CA—Direct oral anticoagulants (DOACs) don’t reduce device-related thrombosis (DRT) compared with dual antiplatelet therapy (DAPT) following left atrial appendage occlusion (LAAO), but ...

DOACs are effective, whether initiated early or late after stroke. (HealthDay News) — For individuals with minor, moderate, or major stroke, the treatment effect of early versus late direct oral ...

People with atrial fibrillation (Afib) who took low doses of blood-thinning drugs known as direct oral anticoagulants (DOACs) experienced more bleeding during the first three months of treatment.